Deals to Restrain Generic Drugs Face a Ban

The head of The Federal Trade Commission and a group of House lawmakers want Congress to add a provision in the healthcare plan that would prevent name-brand drug makers from paying generic makers to delay competition from cheaper generic alternatives.  This article from The New York Times.